EP1071436A4 - IMMUNE EFFECTOR CELL HYBRIDS - Google Patents

IMMUNE EFFECTOR CELL HYBRIDS

Info

Publication number
EP1071436A4
EP1071436A4 EP99903347A EP99903347A EP1071436A4 EP 1071436 A4 EP1071436 A4 EP 1071436A4 EP 99903347 A EP99903347 A EP 99903347A EP 99903347 A EP99903347 A EP 99903347A EP 1071436 A4 EP1071436 A4 EP 1071436A4
Authority
EP
European Patent Office
Prior art keywords
effector cells
immune effector
hybrid immune
hybrid
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99903347A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1071436A1 (en
Inventor
Bruce L Roberts
Charles A Nicolette
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Genzyme Corp
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of EP1071436A1 publication Critical patent/EP1071436A1/en
Publication of EP1071436A4 publication Critical patent/EP1071436A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4257—Mucins, e.g. MUC-1

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP99903347A 1998-01-26 1999-01-25 IMMUNE EFFECTOR CELL HYBRIDS Withdrawn EP1071436A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8835798P 1998-01-26 1998-01-26
US88357P 1998-01-26
US8004198P 1998-03-31 1998-03-31
US80041P 1998-03-31
PCT/US1999/001464 WO1999037313A1 (en) 1998-01-26 1999-01-25 Immune effector cell hybrids

Publications (2)

Publication Number Publication Date
EP1071436A1 EP1071436A1 (en) 2001-01-31
EP1071436A4 true EP1071436A4 (en) 2003-08-27

Family

ID=26762993

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99903347A Withdrawn EP1071436A4 (en) 1998-01-26 1999-01-25 IMMUNE EFFECTOR CELL HYBRIDS

Country Status (5)

Country Link
EP (1) EP1071436A4 (enExample)
JP (2) JP2002500872A (enExample)
AU (1) AU2339299A (enExample)
CA (1) CA2318987A1 (enExample)
WO (1) WO1999037313A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020142974A1 (en) * 1998-09-11 2002-10-03 Leonard D. Kohn Immune activation by double-stranded polynucleotides
EP1168924A4 (en) * 1999-03-31 2002-09-04 Univ Pittsburgh DERIVATIVED IMMUNOGENES IN VITRO INDUCTION OF ANTIQUE-SPECIFIC T-CELLS USING DENDRITIC CELL-TUMOR CELL OR DENDRITIC CELL-VIRAL CELL
DE60226853D1 (de) * 2001-02-20 2008-07-10 Ortho Mcneil Pharm Inc Zelltherapieverfahren für die behandlung von tumoren
US20040071671A1 (en) 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
FR2828934B1 (fr) * 2001-08-27 2004-08-13 Inst Nat Sante Rech Med Test de l'immunite cellulaire par des peptides fixes sur support solide
AU2003275767A1 (en) * 2002-11-07 2004-06-07 Johnson & Johnson Research Pty Limited A means of producing and utilising a population of disease specific cytotoxic T-lymphocytes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002156A1 (en) * 1992-07-16 1994-02-03 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate t cells
WO1998046785A1 (en) * 1997-04-15 1998-10-22 Dana-Farber Cancer Institute, Inc. Dendritic cell hybrids

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002156A1 (en) * 1992-07-16 1994-02-03 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate t cells
WO1998046785A1 (en) * 1997-04-15 1998-10-22 Dana-Farber Cancer Institute, Inc. Dendritic cell hybrids

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ALBERT M L ET AL: "IMMATURE DENDRITIC CELLS PHAGOCYTOSE APOPTOTIC CELLS VIA ALPHA V BETA 5 AND CD36, AND CROSS-PRESENT ANTIGENS TO CYTOTOXIC T LYMPHOCYTES", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 188, no. 7, 5 October 1998 (1998-10-05), pages 1359 - 1368, XP000906793, ISSN: 0022-1007 *
ALBERT MATTHEW L ET AL: "Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 392, no. 6671, 5 March 1998 (1998-03-05), pages 86 - 89, XP002154749, ISSN: 0028-0836 *
CELLUZZI C M ET AL: "Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 160, no. 7, 1 April 1998 (1998-04-01), pages 3081 - 3085, XP002167051, ISSN: 0022-1767 *
DUNNION D ET AL: "Human antigen presenting cell/tumour cell hybrids as candidate cancer vaccines", EUROPEAN JOURNAL OF IMMUNOGENETICS 1998 UNITED KINGDOM, vol. 25, no. 1, 1998, pages 58, XP009007824, ISSN: 0960-7420 *
GONG J ET AL: "INDUCTION OF ANTIGEN-SPECIFIC ANTITUMOR IMMUNITY WITH ADENOVIRUS- TRANSDUCED DENDRITIC CELLS", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 4, no. 10, October 1997 (1997-10-01), pages 1023 - 1028, XP002910552, ISSN: 0969-7128 *
GONG J L ET AL: "FUSION OF HUMAN BREAST TUMOR AND DENDRITIC CELLS AS A NOVEL ANTITUMOR VACCINE", PROCEEDINGS OF THE 89TH. ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. NEW ORLEANS, LA, MARCH 28 - APRIL 1, 1998, PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, PHILADELPHIA, PA: AACR, US, vol. 39, March 1998 (1998-03-01), pages 172, XP002910557 *
GUO YAJUN ET AL: "Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 263, no. 5146, 28 January 1994 (1994-01-28), pages 518 - 520, XP002167016, ISSN: 0036-8075 *
JIANLIN GONG ET AL: "INDUCTION OF ANTITUMOR ACTIVITY BY IMMUNIZATION WITH FUSIONS OF DENDRITIC AND CARCINOMA CELLS", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 3, no. 5, May 1997 (1997-05-01), pages 558 - 561, XP002919846, ISSN: 1078-8956 *
LESPAGNARD L ET AL: "DENDRITIC CELLS FUSED WITH MASTOCYTOMA CELLS ELICIT THERAPEUTIC ANTITUMOR IMMUNITY", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 76, 1998, pages 250 - 258, XP002951123, ISSN: 0020-7136 *
See also references of WO9937313A1 *
WANG J ET AL: "Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines", JOURNAL OF IMMUNOLOGY 15 NOV 1998 UNITED STATES, vol. 161, no. 10, 15 November 1998 (1998-11-15), pages 5516 - 5524, XP002234896, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
AU2339299A (en) 1999-08-09
CA2318987A1 (en) 1999-07-29
EP1071436A1 (en) 2001-01-31
JP2002500872A (ja) 2002-01-15
WO1999037313A1 (en) 1999-07-29
JP2009195235A (ja) 2009-09-03

Similar Documents

Publication Publication Date Title
DE69501195D1 (de) Hybride halbleiteranordnung
DE69942848D1 (de) Batterieladegerät
DE69940252D1 (de) Batteriepaket
DE69923895D1 (de) Batterieladegerät
DE60018791D1 (de) Lithium batterien
DE69908286T8 (de) Batterieseparator
DE60042798D1 (de) Batteriesatz
DE60040185D1 (de) Batteriesatz
DE60030345D1 (de) Batterie-Pack
DE60001887D1 (de) Modular aufgebaute Batterie
DE69935628D1 (de) Hybridmodul
DE19782071T1 (de) Hybride, schwimmende Bürstendichtung
DE69842150D1 (de) Batteriestromversorgung
DE69933278D1 (de) Batterie
EP0971430A4 (en) Battery
DE69815474D1 (de) Hybride Schweissvorrichtung
NO20010797L (no) Enzym-batteri
DE69902721D1 (de) Batterie
FR2773268B1 (fr) Batterie bipolaire
DE60000321D1 (de) Modulare Batterie
DE60019498D1 (de) Batteriepack
DE50005461D1 (de) Zwei-batteriensystem
FR2784626B1 (fr) Groupe motopropulseur hybride
DE50005631D1 (de) Zwei-batteriensystem
DE60042908D1 (de) Batterielader

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000726

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DANA-FARBER CANCER INSTITUTE, INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20030715

17Q First examination report despatched

Effective date: 20030829

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DANA-FARBER CANCER INSTITUTE, INC.

Owner name: GENZYME CORPORATION

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20101218